G1 Therapeutics reported for 6 months of 2023

G1 Therapeutics' GAAP loss for 6 months of 2023 was $18.885 billion, down 4.7 times from $88.638 billion in the prior year. Revenue increased 3.2 times to $55.338 million compared to $17.475 million a year earlier.